Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Researchers say COVID-19 antibody levels have fallen rapidly in the UK

Number of people testing positive for antibodies fell by 26.5% between June and September

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

Eliminating pharmaceutical rebates, is this déjà vu?

By Andrew Parece and Matthew Majewski

AstraZeneca AZ

AZ’s COVID-19 vaccine shows promise in younger and older adults

Company said vaccine produces similar immune response in younger and older adults

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

- PMLiVE

Bayer’s drop of the future

Digital health isn’t always about digital

- PMLiVE

Vaccine developers call on FDA to offer clarity on COVID-19 trials

Comments from J&J and Pfizer made before FDA advisory committee meeting yesterday

- PMLiVE

Moderna completes enrolment of phase 3 COVID-19 vaccine trial

Late-stage study hits 30,000 participant target

COVID-19 – a catalyst for technology adoption in clinical trials

As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links